Core One Labs Inc. announced the receipt of additional positive results from its second round of Stage 1 animal model studies. The studies were conducted in collaboration with esteemed research partners at the Universitat de Barcelona, Spain, and were carried out on behalf of Core One's wholly owned subsidiary, Akome Biotechnologies Inc. (Akome). These additional positive results come from the animal model studies that tested five carefully selected bioactive compounds based on their ability to mitigate, or eliminate disrupted physiological processes associated with a variety of neurological and mental health disorders, including Alzheimer's Disease ("Alzheimer's"), Parkinson's Disease ("Parkinson's"), Ischemic Stroke ("Stroke") and Depression.

The fact that Akome is testing five compounds (Bio-Compounds A-E) speaks to the Company's diversified drug pipeline, which will allow Core One to potentially develop a number of different pharmaceuticals targeting a wide range of diseases, thereby increasing the company's revenue potential in the long term. On July 24, 2023, Akome unveiled the initial findings from the first round of Stage 1 animal model studies. These results showcased the potential of the plant bio-active compound referred to as "Bio-Compound A," the first among five bio-compounds being investigated in the Company's five United States Patent and Treaty Office applications.

The data from this animal model demonstrated that Bio-Compound A exhibits promising properties in significantly reducing motor dysfunction. This animal model motor dysfunction could be considered a proxy of the motor dysfunction observed in Parkinson's disease and prevalent in the late stages of Alzheimer's disease. Building on this promising foundation, Core One's investigators have now received positive results for the remaining four bio-compounds, namely Bio-Compounds B through E, in the recently concluded Round 2 Stage 1 animal model studies.

These studies were meticulously designed, following the exact testing criteria employed during Round 1. The animal models were individually exposed to various concentrations of the respective Bio-Compounds, and their motility was closely evaluated compared to a control sample of animal models not exposed to the Bio-Compounds. The data from Round 2 studies for each of Bio-Compounds B, C, D, and E demonstrated significant improvement in the animal models' motility when compared to the control sample. Additionally, investigators observed that as the dose concentration of the respective Bio-Compounds increased, the improvement in the model's motility also increased, further underlining the significant potential therapeutic value of the patent pending Bio-Compounds.

The combined significance of the previously reported Round 1 and the current Round 2 Stage 1 animal model studies underscores the enormous promise of all five bio-compounds currently under investigation. As Core One continues its dedication to drug development and pre-clinical testing, these compounds stand as strong contenders for further evaluation and potential breakthroughs in treating motor dysfunction related to neurological disorders like Parkinson's and Alzheimer's.